[HTML][HTML] Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia
HC Murray, K Miller, JS Brzozowski, RGS Kahl… - Molecular & Cellular …, 2023 - ASBMB
Acute myeloid leukemia (AML) is the most common and aggressive form of acute leukemia,
with a 5-year survival rate of just 24%. Over a third of all AML patients harbor activating
mutations in kinases, such as the receptor tyrosine kinases FLT3 (receptor-type tyrosine-
protein kinase FLT3) and KIT (mast/stem cell growth factor receptor kit). FLT3 and KIT
mutations are associated with poor clinical outcomes and lower remission rates in response
to standard-of-care chemotherapy. We have recently identified that the core kinase of the …
with a 5-year survival rate of just 24%. Over a third of all AML patients harbor activating
mutations in kinases, such as the receptor tyrosine kinases FLT3 (receptor-type tyrosine-
protein kinase FLT3) and KIT (mast/stem cell growth factor receptor kit). FLT3 and KIT
mutations are associated with poor clinical outcomes and lower remission rates in response
to standard-of-care chemotherapy. We have recently identified that the core kinase of the …